HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siderowf, A. Articles by Stern, M. Search for Related Content PubMed PubMed Citation Articles by Siderowf, A. Articles by Stern, M.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Clinical trials with rasagiline

Evidence for short-term and long-term effects

From the Parkinson’s Disease and Movement Disorders Center, University of Pennsylvania, Philadelphia, Pennsylvania.

Address correspondence and reprint requests to Dr. Andrew Siderowf, Department of Neurology, 330 South 9^th Street, Second Floor, Philadelphia, PA 19107; e-mail: adsiderowf{at}pahosp.com

Rasagiline (N-propargyl-1 (R)-aminoindan) is a selective, potent irreversible inhibitor of MAO-B that possesses neuroprotective and anti-apoptotic properties in a variety of in vitro and in vivo animal models relevant to Parkinson’s disease (PD). Several randomized controlled clinical trials have demonstrated the safety and efficacy of rasagiline as monotherapy in PD and as adjunctive therapy for patients receiving levodopa. In addition, the 1-year randomized, delayed-start analysis of the TEMPO study suggests that rasagiline may slow the rate of progression of PD. The randomized delayed-start paradigm has potential to differentiate short-term symptomatic effects from long-term effects of anti-parkinsonian agents. In the future, long-term trials to examine the potential disease-modifying effects of rasagiline, which incorporate biological markers as well as clinical endpoints, may further elucidate the role of rasagiline in the treatment of both early and advanced PD.

Publication of this supplement was supported by an educational grant from Teva Neuroscience and Eisai, Inc.

Disclosure: MS has received personal honoraria from the sponsor during his professional career. The sponsor has provided AS with an honorarium for his participation in this project as well as personal honoraria during his career.

This article has been cited by other articles:

				E. Groner, Y. Ashani, D. Schorer-Apelbaum, J. Sterling, Y. Herzig, and M. Weinstock The Kinetics of Inhibition of Human Acetylcholinesterase and Butyrylcholinesterase by Two Series of Novel Carbamates Mol. Pharmacol., June 1, 2007; 71(6): 1610 - 1617. [Abstract] [Full Text] [PDF]